A Biparatopic HER2-Targeting Antibody-Drug Conjugate Induces Tumor Regression in Primary Models Refractory to or Ineligible for HER2-Targeted Therapy
Cancer Cell - United States
doi 10.1016/j.ccell.2015.12.008
Full Text
Open PDFAbstract
Available in full text
Date
January 1, 2016
Authors
Publisher
Elsevier BV